{"entity":{"id":"1987","kind":"year","name":"1987 in oncology","aka":["1987"],"tldr":"Everything OnCo dates to 1987: 30 entries, 14 landmarks, 7 journals founded, 4 papers and 2 companies founded. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"30 dated entries in OnCo fall in 1987: 14 landmarks, 7 journals founded, 4 papers, 2 companies founded, 1 approval, 1 law or regulation and 1 paper listed on a person's page.\n\nOf those, 30 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["1986","1988"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":1987,"events":[{"group":"approval","date":"1987","precision":"year","title":"Mitoxantrone approved in US","note":"Acute non-lymphocytic leukaemia in adults (combination); later hormone-refractory prostate cancer pain (with corticosteroids) and multiple sclerosis","from":"mitoxantrone","refs":[]},{"group":"company","date":"1987","precision":"year","title":"ANSTO (Australian Nuclear Science and Technology Organisation) founded","note":"Lucas Heights, Sydney","from":"ansto","refs":[]},{"group":"company","date":"1987","precision":"year","title":"Canfield Scientific founded","note":"Parsippany, NJ","from":"canfield-scientific","refs":[]},{"group":"history","date":"1987","precision":"year","title":"ATRT described as distinct from medulloblastoma","note":"Atypical teratoid/rhabdoid tumour (ATRT). Rorke and colleagues recognise the rhabdoid tumour of the CNS.","from":"atrt","refs":[]},{"group":"history","date":"1987","precision":"year","title":"BEP becomes the standard (etoposide replaces vinblastine)","note":"Non-seminomatous germ cell tumour","from":"non-seminoma","refs":["etoposide","bleomycin"]},{"group":"history","date":"1987","precision":"year","title":"BEP replaces PVB","note":"Extragonadal germ cell tumour. Etoposide in place of vinblastine gave equal cure with less neurotoxicity in the Indiana and SECSG trials.","from":"extragonadal-germ-cell-tumour","refs":["etoposide"]},{"group":"history","date":"1987","precision":"year","title":"BEP replaces PVB (Williams, NEJM)","note":"Testicular germ cell tumours. Etoposide substitutes vinblastine with better efficacy and less neurotoxicity.","from":"testicular","refs":["etoposide","bleomycin"]},{"group":"history","date":"1987","precision":"year","title":"Cisplatin-5-FU induction and larynx preservation trials begin","note":"Head and neck squamous cell carcinoma. VA Larynx study establishes organ preservation with chemoradiation.","from":"head-and-neck","refs":[]},{"group":"history","date":"1987","precision":"year","title":"Extracorporeal photopheresis approved for cutaneous T-cell lymphoma","note":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","from":"cutaneous-t-cell-lymphoma","refs":["methoxsalen-ecp"]},{"group":"history","date":"1987","precision":"year","title":"HER2 amplification found in 30 percent of breast cancers and tied to early relapse","note":"Triple-negative breast cancer (TNBC). Slamon and colleagues, 189 tumours. With the oestrogen and progesterone receptor assays it completed the three tests whose absence defines tri...","from":"tnbc","refs":["paper-slamon-her2-amplification-science-1987","her2"]},{"group":"history","date":"1987","precision":"year","title":"Histiocyte Society founded; disease renamed Langerhans cell histiocytosis","note":"Single-system Langerhans cell histiocytosis (bone, skin or one other organ)","from":"lch-single-system","refs":[]},{"group":"history","date":"1987","precision":"year","title":"Lewis-negative patients shown unable to make CA 19-9","note":"Pancreatic ductal adenocarcinoma. Tempero and colleagues, 20 patients: a normal marker never rules the cancer out.","from":"pancreatic","refs":["paper-tempero-ca19-9-lewis-antigens-cancer-res-1987","ca19-9"]},{"group":"history","date":"1987","precision":"year","title":"Octreotide approved","note":"Neuroendocrine tumours","from":"neuroendocrine","refs":[]},{"group":"history","date":"1987","precision":"year","title":"Prostate-specific antigen becomes a marker","note":"Prostate cancer. Stamey measured the antigen in 2,200 samples from 699 patients: it tracked tumour volume, fell to undetectable after prostatectomy with a half-life of 2.2 days, an...","from":"prostate","refs":["paper-stamey-psa-serum-marker-nejm-1987"]},{"group":"history","date":"1987","precision":"year","title":"Slamon shows HER2 amplification marks aggressive disease, and a drug target","note":"HER2-positive breast cancer. Science paper identifying HER2/neu amplification in 25-30% of breast cancers.","from":"breast-her2-positive","refs":["her2"]},{"group":"history","date":"1987","precision":"year","title":"Slamon: HER2 amplification marks aggressive disease","note":"Early HER2-positive breast cancer","from":"her2-positive-early-breast-cancer","refs":[]},{"group":"history","date":"1987","precision":"year","title":"The 4 mm margin is measured rather than agreed","note":"Skin cancer (all types). 117 basal cell carcinomas marked in 2 mm increments before Mohs surgery showed that 4 mm clears more than 95 per cent of tumours under 2 cm; the 1992 compa...","from":"skin-cancer","refs":["surgical-margins-keratinocyte-cancer"]},{"group":"journal","date":"1987","precision":"year","title":"Acta oncologica founded","note":"Medical Journals Sweden AB (MJS Publishing)","from":"acta-oncologica","refs":[]},{"group":"journal","date":"1987","precision":"year","title":"Genes & Development founded","note":"Cold Spring Harbor Laboratory Press","from":"genes-and-development","refs":[]},{"group":"journal","date":"1987","precision":"year","title":"Hematology/oncology clinics of North America founded","note":"Elsevier","from":"hematology-oncology-clinics-of-north-america","refs":[]},{"group":"journal","date":"1987","precision":"year","title":"In vivo founded","note":"International Institute of Anticancer Research (IIAR)","from":"in-vivo","refs":[]},{"group":"journal","date":"1987","precision":"year","title":"Leukemia founded","note":"Springer Nature","from":"leukemia","refs":[]},{"group":"journal","date":"1987","precision":"year","title":"Oncogene founded","note":"Springer Nature (Nature Portfolio)","from":"oncogene-journal","refs":[]},{"group":"journal","date":"1987","precision":"year","title":"Oncology (Williston Park) founded","note":"MJH Life Sciences","from":"oncology-williston-park","refs":[]},{"group":"law","date":"1987","precision":"year","title":"Expanded access (compassionate use)","note":"United States, regulation.","from":"expanded-access","refs":[]},{"group":"paper","date":"1987","precision":"year","title":"Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate","note":"Stamey TA, Yang N, Hay AR, et al. New England Journal of Medicine.","from":"paper-stamey-psa-serum-marker-nejm-1987","refs":[]},{"group":"paper","date":"1987","precision":"year","title":"Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer","note":"Tempero MA, Uchida E, Takasaki H, et al. Cancer Research.","from":"paper-tempero-ca19-9-lewis-antigens-cancer-res-1987","refs":[]},{"group":"paper","date":"1987","precision":"year","title":"Slamon 1987: HER2 gene amplification marks an aggressive form of breast cancer","note":"Slamon DJ, Clark GM, Wong SG, et al. Science.","from":"paper-slamon-her2-amplification-science-1987","refs":[]},{"group":"paper","date":"1987","precision":"year","title":"Treatment of disseminated germ cell tumours with cisplatin, bleomycin and either vinblastine or etoposide","note":"Williams SD, Birch R, Einhorn LH, et al. New England Journal of Medicine.","from":"paper-williams-bep-vs-pvb-nejm-1987","refs":[]},{"group":"person-paper","date":"1987","precision":"year","title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene","note":"Science","from":"dennis-slamon","refs":[]}]},"route":"/years/1987/","neighbours":{"year":[{"id":"1986","kind":"year","name":"1986 in oncology","route":"/years/1986/"},{"id":"1988","kind":"year","name":"1988 in oncology","route":"/years/1988/"}]}}